PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[Kronberg]

Yes this is a tough question. I do not particularly care about institutional investors. My DD says that about 30% of all Fabry patients have problem with renal function.So in case of success of OPRX-102, they can very quickly get ~1500 patients.It should turn into a revenue of about $450-500M or about $100-125M for Protalix IMO.Plus they can get a lot of patients for treatment on a monthly basis instead of every two weeks. In case this treatment is the gold standard therapy success will be even greater.And we are talking about only one indication.How can the market give the company today's M/C remains a big mystery.